CSL Limited

ASX:CSL.AX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

🔍 Research & Consulting

Location

Australia

Market Cap

USD 74.97 B

Share Price

USD 154.82

Avg Daily Volume

902,529

Change (1 day)

0.08%

Change (1 year)

-19.99%

Change (YTD)

-11.16%

CSL Limited Gross Profit Margin for the year ending June 30, 2024: 51.47%

CSL Limited Gross Profit Margin is 51.47% for the year ending June 30, 2024, a 6.50% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

CSL Limited Gross Profit Margin for the year ending June 30, 2023 was 48.33%, a -8.90% change year over year.
CSL Limited Gross Profit Margin for the year ending June 30, 2022 was 53.05%, a -4.50% change year over year.
CSL Limited Gross Profit Margin for the year ending June 30, 2021 was 55.55%, a -0.94% change year over year.
CSL Limited Gross Profit Margin for the year ending June 30, 2020 was 56.08%, a 2.71% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

ASX: CSL.AX

CSL Limited

CEO	Dr. Paul F. McKenzie Ph.D.
IPO Date	June 1, 1994
Location	Australia
Headquarters	45 Poplar Road
Employees	32,698
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals 🔍 Research & Consulting

Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.